A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of BTX 1204 in Patients with Mild to Moderate Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Botanix Pharmaceuticals
- 04 Sep 2018 Status changed from recruiting to completed.
- 06 Jun 2018 Results presented in the Botanix Pharmaceuticals media release.
- 19 Feb 2018 Planned End Date changed from 31 Jan 2018 to 30 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History